155
Participants
Start Date
March 24, 2017
Primary Completion Date
July 31, 2017
Study Completion Date
July 31, 2017
GSP304 (tiotropium bromide) Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer
GSP304 Placebo Inhalation Solution
Once daily (QD) oral inhalation using a nebulizer
Spiriva® Respimat® inhalation spray
Once daily (QD) oral inhalation
Glenmark Investigational Site 9, Charlotte
Glenmark Investigational Site 15, Spartanburg
Glenmark Investigational Site 7, Spartanburg
Glenmark Investigational Site 2, Greenville
Glenmark Investigational Site 4, Greenville
Glenmark Investigational Site 3, Easley
Glenmark Investigational Site 1, Rock Hill
Glenmark Investigational Site 20, Ormond Beach
Glenmark Investigational Site 19, Edgewater
Glenmark Investigational Site 13, Winter Park
Glenmark Investigational Site 6, Orlando
Glenmark Investigational Site 21, Vero Beach
Glenmark Investigational Site 10, Miami Lakes
Glenmark Investigational Site 24, Miami
Glenmark Investigational Site 16, Miami
Glenmark Investigational Site 23, Andalusia
Glenmark Investigational Site 8, Dublin
Glenmark Investigational Site 5, Columbus
Glenmark Investigational Site 22, Columbus
Glenmark Investigational Site 25, Tomball
Glenmark Investigational Site 12, Phoenix
Glenmark Investigational Site 14, Tempe
Glenmark Investigational Site 18, Las Vegas
Glenmark Investigational Site 17, Fullerton
Glenmark Investigational Site 11, Medford
Glenmark Specialty S.A.
INDUSTRY